Page 9 - Us Market

Sun Pharmaceutical launches Cequa to treat dry eye disease in US market

Cequa is indicated to increase tear production in patients with dry eye, Sun Pharma said

Railways draws road map for FY20, plans to raise $1 bn in US market

IRFC has appointed arrangers in the US for the bond issue. Insurance companies and pension funds are likely to subscribe to them

Pricing pressure the new worry for Indian pharma

The intense pricing pressure in the US market, reflected in the 26 per cent dip in net sales of Sun Pharma's US subsidiary Taro Pharma, saw India's largest pharma company lose nearly 8 per cent in intra-day trade on Tuesday. The stock closed 4.3 per cent down at Rs 612.55 at the end of days' trading. The price correction was not limited to Sun Pharma with all pharma majors either hitting their 52-week or yearly lows. The BSE Healthcare index was the biggest loser among sectoral indices shedding over 3 per cent on Tuesday. Thus far in the calendar year 2017, the Nifty Pharma index has underperformed with a fall of nearly 6%, as compared to a rally of around 14-15% in the Nifty50 and the S&P BSE Sensex.Among individual stocks, Lupin, Aurobindo Pharma, Divi's Laboratories, Glenmark Pharmaceuticals, Indoco Remedies, Strides Shasun and Wockhardt hit their respective 52-week low on the BSE in intra-day trade on Tuesday.The drop in Taro revenues came despite the 3 per cent increase in ...

Jeff Sommer: The US bull run may stretch a while

Stocks are likely to stay buoyant, owing to the friendly interest rate and corporate earnings environment

Merger pop missing from US market

Slowdown in deal activity means smaller boost to share prices